Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, Jan. 11, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
-
NEW YORK, Nov. 17, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
-
Allogeneic off-the-shelf iNKT cell therapy, agenT-797, alone and in combination with pembro/nivo reports early clinical activity in solid tumors, with 27% and 66% of patients, respectively, had a...
-
- Five presentations on clinical data and novel pipeline candidates at the Society of Cancer Immunotherapy (SITC) Meeting- R&D Day on November 10, 2022, from 4:00-6:00pm ET in Boston and via...
-
NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
-
Experts in disease pathways discuss clinical data of allo-iNKTsR&D strategy driving pipeline momentum, productivity, and innovationInternal scalable manufacturing of fully allogeneic iNKT cells;...
-
Clinical data on AgenT-797, allogeneic (allo) iNKTs, +/- anti-PD-1 in advanced solid tumorsClinical data of AgenT-797 in viral ARDS and refractory multiple myelomaNew therapeutic candidates: 1)...
-
NEW YORK, Aug. 31, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...
-
Novel stromal-CAR-iNKT shows activity in solid tumors; FIH planned for 2023Clinical presentation of AgenT-797 in solid tumors, myeloma, and ARDS planned for 2H2022Under the leadership team of Dr. Joy...
-
NEW YORK, Aug. 02, 2022 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic,...